NASDAQ:VBLT - Vascular Biogenics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.27 -0.11 (-7.97 %) (As of 11/13/2018 02:15 AM ET)Previous Close$1.38Today's Range$1.24 - $1.3152-Week Range$1.24 - $9.05Volume113,900 shsAverage Volume234,077 shsMarket Capitalization$49.52 millionP/E Ratio-3.43Dividend YieldN/ABeta-1.25 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and in Phase III clinical trials for recurrent platinum-resistant ovarian cancer, as well as for Phase II clinical trials for iodine-resistant differentiated thyroid cancer. The company is also developing VB-111, which is in Phase I clinical trials for the treatment of patients with various types of advanced metastatic cancer types, including thyroid cancer, neuroendocrine cancer, renal cell carcinoma, and lung cancer. In addition, it is developing VB-511, an anti-angiogenic candidate for oncology; VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases; VB-201, a Lecinoxoid-based compound for the control of chronic inflammatory disorders; and VB-600 that is in pre-clinical stage for targeting of MOSPD2 for immuno-oncology and anti-inflammatory applications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Modi'in, Israel. Receive VBLT News and Ratings via Email Sign-up to receive the latest news and ratings for VBLT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VBLT Previous SymbolNASDAQ:VBLX CUSIPN/A Webwww.vblrx.com Phone972-8993-5000 Debt Debt-to-Equity Ratio0.01 Current Ratio10.45 Quick Ratio10.45 Price-To-Earnings Trailing P/E Ratio-3.43 Forward P/E Ratio-1.84 P/E GrowthN/A Sales & Book Value Annual Sales$13.86 million Price / Sales3.29 Cash FlowN/A Price / CashN/A Book Value$1.88 per share Price / Book0.68 Profitability EPS (Most Recent Fiscal Year)($0.37) Net Income$-10,130,000.00 Net MarginsN/A Return on Equity-23.24% Return on Assets-19.85% Miscellaneous Employees37 Outstanding Shares35,880,000Market Cap$49.52 million OptionableOptionable Vascular Biogenics (NASDAQ:VBLT) Frequently Asked Questions What is Vascular Biogenics' stock symbol? Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT." How were Vascular Biogenics' earnings last quarter? Vascular Biogenics Ltd (NASDAQ:VBLT) posted its quarterly earnings results on Thursday, August, 16th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.05. The biopharmaceutical company had revenue of $0.18 million for the quarter, compared to analysts' expectations of $0.30 million. View Vascular Biogenics' Earnings History. When is Vascular Biogenics' next earnings date? Vascular Biogenics is scheduled to release their next quarterly earnings announcement on Tuesday, November 13th 2018. View Earnings Estimates for Vascular Biogenics. What price target have analysts set for VBLT? 4 analysts have issued twelve-month price targets for Vascular Biogenics' stock. Their forecasts range from $3.00 to $4.00. On average, they expect Vascular Biogenics' share price to reach $3.3333 in the next twelve months. This suggests a possible upside of 162.5% from the stock's current price. View Analyst Price Targets for Vascular Biogenics. What is the consensus analysts' recommendation for Vascular Biogenics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vascular Biogenics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Vascular Biogenics. Has Vascular Biogenics been receiving favorable news coverage? Media coverage about VBLT stock has been trending negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Vascular Biogenics earned a coverage optimism score of -2.7 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future. Who are some of Vascular Biogenics' key competitors? Some companies that are related to Vascular Biogenics include Newron Pharmaceuticals (NWPHF), Galectin Therapeutics (GALT), Intec Pharma (NTEC), Ardelyx (ARDX), Bellicum Pharmaceuticals (BLCM), Calithera Biosciences (CALA), Spring Bank Pharmaceuticals (SBPH), REDHILL BIOPHAR/S (RDHL), Xenon Pharmaceuticals (XENE), Cerecor (CERC), Poxel (PXXLF), Nature's Sunshine Products (NATR), Teligent (TLGT), ContraFect (CFRX) and Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM). Who are Vascular Biogenics' key executives? Vascular Biogenics' management team includes the folowing people: Prof. Dror Harats, CEO & Director (Age 61)Mr. Amos Ron, CFO, Principal Accounting Officer & Company Sec. (Age 63)Dr. Erez Feige, VP of Bus. Operations (Age 44)Dr. Eyal Breitbart, VP of Research & Operations (Age 51)Dr. Naamit Sher, VP of Drug Devel. & Regulatory (Age 64) How do I buy shares of Vascular Biogenics? Shares of VBLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Vascular Biogenics' stock price today? One share of VBLT stock can currently be purchased for approximately $1.27. How big of a company is Vascular Biogenics? Vascular Biogenics has a market capitalization of $49.52 million and generates $13.86 million in revenue each year. The biopharmaceutical company earns $-10,130,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. Vascular Biogenics employs 37 workers across the globe. What is Vascular Biogenics' official website? The official website for Vascular Biogenics is http://www.vblrx.com. How can I contact Vascular Biogenics? Vascular Biogenics' mailing address is 8 HaSatat St, Modi'in L3, 7178106. The biopharmaceutical company can be reached via phone at 972-8993-5000 or via email at [email protected] MarketBeat Community Rating for Vascular Biogenics (NASDAQ VBLT)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 193 (Vote Outperform)Underperform Votes: 202 (Vote Underperform)Total Votes: 395MarketBeat's community ratings are surveys of what our community members think about Vascular Biogenics and other stocks. Vote "Outperform" if you believe VBLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VBLT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/13/2018 by MarketBeat.com StaffFeatured Article: Why do companies engage in swaps?